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Background: To evaluate the potential efficacy of preventive effect of ulinastatin in esophagectomy patients.
Methods: Eighty patients with esophageal cancer were preoperatively allocated at random into two equal groups.
Ulinastatin was administered to the treatment group (U) whereas the control group (C) received a placebo. The
arterial oxygen tension and carbon dioxide tension were measured and the respiratory index (RI) was calculated.
Plasma levels of circulating T lymphocyte subsets and interleukin 6 (IL-6) were measured and clinical courses of
patients in the two groups were compared.
Results: RI in the U group was significantly lower than that in the C group. The rate of postoperative complications
and the duration of ICU stay were significantly lower in the U group. Ulinastatin significantly increased the rate of
CD3+ and CD4+ cells, and ratio of CD4+/CD8+, but decreased the rate of CD8+ cells and release of IL-6 compared to
the C group on postoperative days 1 and 3. Patients within the C group showed worse recurrence free survival.
Multivariate analysis revealed that ulinastatin administration significantly decreased the incidence of recurrence.
Conclusions: Ulinastatin had a preventive effect on postoperative complications and immunosuppression in
esophagectomy patients, thereby prolongingrecurrence free survival.
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Surgery remains the most effective treatment for solid
tumors including esophageal cancer. However, esopha-
gectomy, one of the most invasive procedures among
gastrointestinal operations, has a high frequency of post-
operative complications [1]. Several responsible back-
ground factors have been proposed to explain the broad
spectrum of postoperative complications after such in-
vasive procedures. The most important ones are syste-
mic inflammatory response syndrome and compensatory
anti-inflammatory cytokine response syndrome [2-4].
Moreover, surgical stress can cause immunosuppres-
sion in response to the complex interaction of various* Correspondence: jgx666@126.com; zmx3115@163.com
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reproduction in any medium, provided the orhormones, cytokines, and acute phase reactants [5]. It
has been reported that perioperative and postoperative
immunosuppression increases the ratio of recurrence
and adversely affects the prognosis of cancer patients
[6,7]. Therefore, it is desirable to find an effective
countermeasure against the overproduction of proin-
flammatory cytokines, postoperative complications, and
immunosuppression.
Ulinastatin is a serine protease inhibitor with a mo-
lecular weight of ~67,000 found in healthy human urine.
It is used worldwide for patients with inflammatory dis-
orders, including disseminated intravascular coagulation,
shock, and pancreatitis [8-10]. Furthermore, ulinastatin
administration can help reduce the surgical stress, pre-
vent radiation-induced lung injury, and modulate im-
mune functions [11-13].
The aim of the present study was to evaluate the
potential efficacy of preventive effect of ulinastatin onLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.






Age 56 ± 12 56 ± 10 0.861
Gender(male/female) 34/6 33/7 0.762
TNM stage(I/II/III) 7/18/15 6/20/14 0.897
Length of resection (cm) 10 ± 4.8 11 ± 4.0 0.157
Number of lymph node dissection 11 ± 4.1 10 ± 4.6 0.154
Alcohol consumption (yes/no) 25/15 23/17 0.648
Smoker(yes/no) 21/19 20/20 0.823
FEV1/FVC(%) 85.3 ± 3.3 85.1 ± 4.3 0.769
ASA classification (I/II) 18/22 17/23 0.822
Duration of operation (min) 206 ± 44 207 ± 43 0.918
Duration of anesthesia (min) 240 ± 46 242 ± 44 0.862
Blood loss during operation (mL) 520 ± 43 518 ± 62 0.903
Figure 1 Effect of ulinastatin on respiratory index. Respiratory
index (RI) in the ulinastatin group (U) was significantly lower than
that in the control group (C) 1 hour after one-lung ventilation (T2)
and the time of sternal closure (T3; P < 0.05). The RI was
calculated as a marker of lung damage using the following
formulas: RI = [FIO2 × (760–47) - PaCO2/0.8]/PaO2.
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Methods
Patients
Between January 2007 and December 2007, patients with
lower thoracic esophageal cancer requiring surgical in-
tervention at the First Affiliated Hospital and Second
Affiliated Hospital, Medical College of Xi’an Jiaotong
University, were enrolled. Exclusion criteria: prior che-
motherapy or irradiation or immunosuppressive drug
administration; blood loss ≥ 1,000 mL; ASA classifica-
tion ≥ III, histological type of adenocarcinoma. Eighty
patients were subsequently randomized into two groups:
control group (C, n = 40) and ulinastatin group (U, n = 40).
The operative procedure for removal of the cancer was
performed by a single surgical team and through the left
posterolateral thoracotomy approach with combined tho-
racoabdominal lymphatic dissection, proximal gastric re-
section and mobilization of the stomach for esophageal
replacement. Institutional Ethics Committee approval for
this project was obtained. Written informed consent was
obtained from each patient before randomization. The
study was designed as a single blinded study. Ulinastatin
(Miraclid, Mochida Pharmaceulinastatincal, Japan) was
administered to the U group as a bolus of 200,000 U
diluted in 20 mL of normal saline every 24 h from 3
days pre-operation until 3 days post-operation.
Clinical course evaluation
Clinical course was evaluated based on rate of postope-
rative complications, including cardiovascular complica-
tions (arrhythmia, pulmonary embolism, and myocardial
infarction), pulmonary complications (pneumonia, ate-
lectasis, pulmonary edema), and others (esophagogastric
anastomosis leakage, stenosis, and wound infection). The
criteria of postoperative complications, especially for pul-
monary complications, were described as before [14]. The
duration of ICU and hospital stay was also determined.
All patients received cisplatin-based postoperative ad-
juvant chemotherapy or standard radiotherapy, if required.
The follow-up period ranged from 1 to 48 months
(median, 35.7 months). Computed tomography (CT) was
performed at least every 6 months to detect recurrence.
Sample collection and assay
Arterial blood was collected immediately at 10 minutes
after operation began (T1), 1 hour after one-lung ventila-
tion (T2), and at the time of closure (T3). Arterial oxygen
tension (PaO2) and carbon dioxide tension (PaCO2) were
measured by blood gas analysis. The respiratory index
(RI) was calculated as a marker of lung damage using the
following formulas: RI = [FIO2 × (760–47) - PaCO2/0.8]/
PaO2. Peripheral whole blood samples were obtained1 hour before surgery (D0) and on postoperative days
1, 3, and 7 (D1, D2, and D3). Lymphocyte subsets
were counted by a FACSCalibur (Becton Dickinson,
San Jose, CA, USA) flow cytometer. Cytokine levels
(IL-6) were determined by ELISA, using commercially
available kits (R&D Systems, Minneapolis, MN, USA).Statistics
Data are expressed as mean ± standard deviation. Sta-
tistical analysis was performed with the SPSS software
package (version 13.0, SPSS Institute). Continuous vari-
ables were analyzed using repeated measures ANOVA
and categorical data were compared by the χ2 test or
Fisher’s exact test. Survival curves were estimated by the
Kaplan-Meier method with the log-rank test. Multivari-
ate analysis was performed using the Cox proportional
hazard regression analysis. P values < 0.05 were consi-
dered significant.







Cardiovascular complications 1 1 1
Pulmonary complications 8 1 0.034
Anastomosis leakage 1 1 1
Anastomosis stenosis 1 0 1
Wound infection 1 1 1
Total 12 4 0.034
Death 1 0 1
Duration of ICU stay (hours) 45 ± 24 33 ± 16 0.01
Length of hospital stay (days) 11 ± 4 10 ± 2 0.170
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Baseline characteristics of enrolled patients
During a period of 12 months between January 2007 and
December 2007, 80 patients undergoing esophagecto-
my were enrolled in this study. Background factors forFigure 2 Effect of ulinastatin on lymphocyte subsets and IL-6. Ulinasta
CD4+ (B) cells, and ratio of CD4+/CD8+ (D), but decreased the rate of CD8+
postoperative days 1 (D1) and 3 (D2; P < 0.05). D0 = 1 hour before surgery, Desophageal cancer patients are listed in Table 1. There
were no significant differences between the groups in
average age, gender, TNM stage, length of resection,
number of lymph node dissection, alcohol consumption,
smoking, ASA classification, duration of operation, dur-
ation of anesthesia, and blood loss during operation.
Type of anesthesia was the same between the two
groups. There were also no significant differences in peri-
operative management, including the usage of steroid and
elastase inhibitor, infusion and nutritional support, and
NSAIDs and other analgesics, between the two groups.Effect of ulinastatin on respiratory index
RI before operation did not differ significantly between
the groups (group U vs. C, 0.29 ± 0.07 vs. 0.31 ± 0.06),
and there were significant time-dependent changes in RI
value in both groups (P < 0.05, Figure 1). Group U sho-
wed significantly lower RI values than that of group C,
both at 1 hour after one-lung ventilation (T2) (0.40 ± 0.09tin (U) administration significantly increased the rate of CD3+ (A) and
(C) cells and release of IL-6 (E) compared to control group (C) on
3 = Postoperative day 7.
Figure 3 Kaplan-Meier survival analysis. Cumulative recurrence free survival differences between patients in the C and U groups. Patients
within the C group showed worse recurrence free survival. P value was obtained using the log-rank test of the difference.
Table 3 Multivariate cox proportional hazards analysis
for recurrence free survival
Variables Recurrence free survival P
RR 95% CI
Ulinastatin administration 0.149 0.063-0.351 <0.05
TNM 1.812 0.652-5.038 0.254
Alcohol consumption 2.066 0.909-4.344 0.757
Smoking 1.088 0.534-2.217 0.817
Gender 0.916 0.425-1.973 0.822
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(T3) (0.75 ± 0.16 vs. 0.90 ± 0.17, P < 0.05).
Effect of ulinastatin on postoperative clinical course
The postoperative clinical course of each patient was care-
fully monitored daily, and complications were checked
(Table 2). Postoperative complications were observed in
12 patients (30%) in the C group and 4 patients (10%) in
the U group, respectively (P < 0.05). A significant decrease
in pulmonary complications was observed in the U group
(P < 0.05), and one patient in the C group died of pul-
monary oedema. Although length of hospital stay showed
no significant differences between the two groups, the
duration of ICU stay was significantly shorter in the U
group (P < 0.05).
As can be seen from Figure 2, ulinastatin administra-
tion significantly increased the rate of CD3+ and CD4+
cells, and ratio of CD4+/CD8+, but decreased the rate of
CD8+ cells and release of IL-6 compared to the C group
on D1 and D2 (P < 0.05).
Side effects
No patient experienced side effects related to ulinastatin
administration; namely, shock, itching, rash, nausea, vo-
miting, or neutropenia.
Survival analysis
Of 80 patients in the database, one patient died in the C
group during the perioperative period, and 3 were lost
to follow-up. As a result, 76 patients were enrolled for
survival analysis. The recurrence rate of the U group
was 57.5% compared to 72.5% in the C group. The most
common recurrence pattern was locoregional recurrence(60% in the U group and 72% in the C group), while
other patients developed systemic recurrence or a com-
bination of both. Recurrence-free survival of all patients
was 33.8 ± 1.7 months, and it was statistically better
for the U group (39.4 ± 2.2) compared to the C group
(27.8 ± 2.4) by Kaplan-Meier analysis (P < 0.05, Figure 3).
Multivariate analysis revealed that ulinastatin adminis-
tration significantly decreased the incidence of recur-
rence (Table 3).
Discussion
Major stressful surgery including esophagectomy always
caused overproduction of proinflammatory cytokines.
The initial proinflammatory response may be uncon-
trolled causing an imbalance between inflammatory re-
sponse syndrome and compensatory anti-inflammatory
cytokine response syndrome, which led to postoperative
complications [15]. For the special surgical procedures,
the risk of pulmonary complications after esophagec-
tomy is higher than any other common operation [16].
Moreover, surgical stress can cause immunosuppression
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nes. In esophageal cancer, a prognostic relation between
the presence of complications and immunosuppression
after esophagectomy and survival has previously been
reported [17,18]. These data suggest that an effective
countermeasure against postoperative complications
and immunosuppression is desirable.
Ulinastatin has many physiological effects in surgical
stress, including the decrease of the inflammatory re-
action, inhibition of immunosuppression, and modifica-
tion of the water balance [13,19,20]. Moreover, previous
studies have shown that ulinastatin inhibits human ovar-
ian cancer and the effect could be related to down-
regulation of protein kinase C [21]. Studies have also
found that ulinastatin enhances the inhibitory effect of
docetaxel in breast cancer by a mechanism consistent
with the down-regulated expression of IL-6, IL-8, and
TNF-α [22]. Since ulinastatin had a preventive effect on
postoperative complications and immunosuppression,
and might inhibit the growth of cancer cells, we chose it
for the certain purpose.
CD3+, CD4+, CD8+ T-lymphocyte percentage and
CD4+/CD8+ ratio were closely related to the cellular im-
mune function and postoperative anti-tumor immunity
[23-25]. Moreover, lower CD3+, lower CD4+ and lower
CD4+/CD8+ ratio were factors independently associated
with worse prognosis of esophageal cancer patients in
different reports [26,27]. Therefore, we investigated ef-
fect of ulinastatin administration on content of lympho-
cyte subsets.
In the present study, it was found that ulinastatin ad-
ministration had a protective effect on pulmonary func-
tion by decreasing the increasing trend of RI during
operation. As a result, the postoperative complications
were lower than that in the C group, especially for pul-
monary complications. Low occurrence of postoperative
complications shortens the duration of ICU stay and de-
creased cost of care. Further, we investigated the effect
of ulinastatin on release of IL-6 and content of lym-
phocyte subsets. The change of post-operative IL-6 and
lymphocyte subsets reflected beneficial effects of uli-
nastatin on anti-inflammatory action, postoperative im-
munosuppression, and postoperative anti-tumor response.
Finally, we observed that the U group had a longer recur-
rence free survival.
Conclusions
From these results we concluded that ulinastatin had
a preventive effect on postoperative complications and
immunosuppression in esophagectomy patients,thereby,
prolonging recurrence free survival. The possible reason
may be that the enhanced anti-tumor response inhibited
tumor metastasis [28,29]. However,the detailed mecha-
nism of action of ulinastatin should be further studied atthe molecular biological level. Evaluation of a large num-
ber of cases is also necessary to assess the clinical useful-
ness of ulinastatin.
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